Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
P/B ratio for Aclaris Therapeutics, Inc. (ACRS)
P/B ratio as of 2023: 0.47
According to Aclaris Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.47. At the end of 2022 the company had a P/B ratio of 5.20.
P/B ratio history for Aclaris Therapeutics, Inc. from 2013 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.47 |
| 2022 | 5.20 |
| 2021 | 4.18 |
| 2020 | 7.31 |
| 2019 | 1.12 |
| 2018 | 1.13 |
| 2017 | 3.08 |
| 2016 | 3.43 |
| 2015 | 1.78 |
| 2014 | -5.65 |
| 2013 | -12.79 |